Drug Price Trends for GUANFACINE HCL ER

Average Pharmacy Cost for GUANFACINE HCL ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
GUANFACINE HCL ER 1 MG TABLET	70436-0039-01	0.17465	EACH	2025-04-23
GUANFACINE HCL ER 1 MG TABLET	60505-3927-01	0.17465	EACH	2025-04-23
GUANFACINE HCL ER 1 MG TABLET	63304-0924-01	0.17465	EACH	2025-04-23
GUANFACINE HCL ER 1 MG TABLET	00228-2850-11	0.17465	EACH	2025-04-23
GUANFACINE HCL ER 1 MG TABLET	62332-0745-31	0.17465	EACH	2025-04-23
GUANFACINE HCL ER 1 MG TABLET	16714-0190-01	0.17465	EACH	2025-04-23
GUANFACINE HCL ER 1 MG TABLET	24979-0533-01	0.17465	EACH	2025-04-23

Market Analysis and Price Projections for Guanfacine HCL ER

Market Overview

The guanfacine hydrochloride extended-release (ER) tablets market is experiencing significant growth, driven by several key factors. Guanfacine HCL ER, commonly known by the brand name Intuniv, is a non-stimulant medication approved for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17 years[1].

Market Size and Growth

As of 2023, the guanfacine hydrochloride tablets market size is estimated to be USD 238.6 million. This market is anticipated to grow to USD 478.4 million by 2033, with a compound annual growth rate (CAGR) of 7.3% from 2024 to 2033[1].

Key Drivers of Market Growth

Increasing Prevalence of ADHD

The rising prevalence of ADHD and growing awareness about the disorder are major drivers for the guanfacine HCL ER market. As more cases are diagnosed, the demand for effective treatment options, including non-stimulant medications like guanfacine, is increasing[1].

Development of Novel Formulations

The development of novel formulations such as extended-release tablets and orally disintegrating tablets is enhancing patient convenience and adherence. These formulations are expected to drive market growth by improving the overall treatment experience for patients[1].

Expanding Indications

Guanfacine HCL ER is being explored for additional indications, including the treatment of oppositional defiant disorder (ODD), conduct disorder (CD), anxiety disorders, tic disorders, and sleep disturbances associated with ADHD. This expansion of indications is likely to create new growth opportunities for the market[1].

Market Segments

Distribution Channels

The retail pharmacy segment dominates the guanfacine HCL ER market due to the wide availability of the drug through retail pharmacies and the convenience of obtaining prescriptions and refills. The online pharmacy segment is also growing rapidly, driven by the increasing adoption of e-prescribing and the preference for online purchasing of medications[1].

Regional Analysis

North America is the largest market for guanfacine HCL ER, driven by the high prevalence of ADHD, a well-established healthcare infrastructure, and favorable reimbursement scenarios. The United States is a major contributor to this market. Europe is the second-largest market, supported by the rising prevalence of ADHD and the increasing focus on mental health. The Asia-Pacific region is projected to witness the highest growth rate during the forecast period, fueled by a large patient population and improving healthcare infrastructure[1].

Price Analysis

Factors Affecting Price

The cost of guanfacine HCL ER can vary based on several factors, including the treatment plan, insurance coverage, and the pharmacy used. Here are some general price ranges:

• Immediate Release (IR) Tablets: The cost for guanfacine 1 mg oral tablet can be around $19 for a supply of 30 tablets[2].
• Extended Release (ER) Tablets: The cost for guanfacine ER tablets can range from $140.64 for 100 tablets of the 1 mg formulation to $283.30 for 100 tablets of the 2 mg formulation[2].

Cost Comparison with Other ADHD Medications

Guanfacine ER tablets, being a generic drug, generally cost less than brand-name drugs like Concerta or Vyvanse. However, the exact cost comparison depends on factors such as the length of treatment, payment assistance programs, and insurance coverage[5].

Savings Strategies

To reduce the cost of guanfacine HCL ER, patients can consider several strategies:

• Using Coupons and Discount Cards: Utilizing coupons and discount cards, such as those offered by Optum Perks, can help lower the cost of the medication[5].
• Getting a 3-Month Supply: Obtaining a 90-day supply of the drug, if approved by the insurance company, can reduce the number of trips to the pharmacy and help lower the overall cost[5].

Challenges and Restraints

Availability of Generic Versions

The availability of generic versions of guanfacine HCL ER can impact market growth, as generics are often preferred due to their lower cost. However, this also means that the market remains competitive, driving innovation and better patient outcomes[1].

Potential Side Effects

The potential side effects associated with guanfacine HCL ER, such as somnolence, fatigue, and nausea, may restrain market growth to some extent. However, these side effects are generally manageable, and the benefits of the medication often outweigh the risks[1][4].

Future Outlook

The guanfacine HCL ER market is poised for steady growth, driven by the increasing prevalence of ADHD, the development of novel formulations, and the expanding indications for the drug. The market is expected to shift towards personalized medicine, taking into account individual patient characteristics and comorbidities, which could further drive the adoption of guanfacine HCL ER as a non-stimulant treatment option[1].

"The guanfacine hydrochloride tablets market is poised for steady growth in the coming years, driven by the increasing prevalence of ADHD, the rising awareness about the disorder, and the growing demand for effective and safe treatment options."[1]

Key Takeaways

• The guanfacine HCL ER market is expected to grow from USD 238.6 million in 2023 to USD 478.4 million by 2033.
• Key drivers include the increasing prevalence of ADHD, development of novel formulations, and expanding indications.
• North America is the largest market, with the Asia-Pacific region expected to witness the highest growth rate.
• The cost of guanfacine HCL ER varies based on treatment plans, insurance, and pharmacies.
• Generic versions and potential side effects may impact market growth.

FAQs

What is guanfacine HCL ER used for?

Guanfacine HCL ER is primarily used for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17 years. It is also being explored for other indications such as oppositional defiant disorder (ODD) and conduct disorder (CD)[1].

How does the cost of guanfacine HCL ER compare to other ADHD medications?

Guanfacine HCL ER, being a generic drug, generally costs less than brand-name drugs like Concerta or Vyvanse. However, the exact cost comparison depends on factors such as treatment length, payment assistance programs, and insurance coverage[5].

What are the potential side effects of guanfacine HCL ER?

Common side effects include somnolence, fatigue, and nausea. These side effects are generally manageable, and the benefits of the medication often outweigh the risks[1][4].

Can I save money on guanfacine HCL ER prescriptions?

Yes, you can save money by using coupons and discount cards, such as those offered by Optum Perks, and by obtaining a 90-day supply of the drug if approved by your insurance company[5].

Is guanfacine HCL ER available in different formulations?

Yes, guanfacine HCL ER is available in immediate-release (IR) and extended-release (ER) formulations. The ER formulation is specifically approved for ADHD treatment, while the IR formulation is used for high blood pressure and other conditions[5].

Which regions are driving the growth of the guanfacine HCL ER market?

North America is the largest market, followed by Europe. The Asia-Pacific region is expected to witness the highest growth rate during the forecast period due to a large patient population and improving healthcare infrastructure[1].

Last updated: 2025-01-02